PRESS RELEASE

NicOx reports financial results for the nine months to September 2011

October 27, 2011. Sophia Antipolis, France. www.nicox.com

NicOx S.A. (NYSE Euronext Paris: COX) today reported financial results for the nine month period ended September 30, 2011, and provided an overview of its activities.

Financial summary for the first nine months of 2011

Following the restructuring of the Group's entities and activities in late 2010, research and development costs and administrative and selling costs were €11.8 million in the nine months to September 30, 2011, compared to €41.4 million for the same period in 2010.

In the first nine months of 2011, NicOx recorded a total net loss for the period of €10.4 million, compared to €37.8 million for the first nine months of 2010. On September 30, 2011, the Company had cash and cash equivalents totalling €96.2 million, compared to €107.3 million on December 31, 2010.

No revenues were recorded for the nine months ended September 30, 2011, compared to €7.4 million for the same period of 2010, which related to the initial license payment received from Bausch + Lomb as part of the worldwide licensing agreement signed in March 2010.

Third quarter operational summary

In July 2011, NicOx formally initiated the Food and Drug Administration's (FDA) Formal Dispute Resolution process regarding the decision not to approve naproxcinod for the relief of the signs and symptoms of osteoarthritis in July 2010. This process enables companies to request a formal review of any FDA decision by raising the matter to the higher supervisory level. If the issue is not resolved at the primary supervisory level, the company may request that the matter be reviewed at additional supervisory levels. NicOx will update the market on the outcome of the appeal when the process is completed.

In August 2011, Jean-Luc Bélingard informed NicOx of his decision to step down from the Board of Directors because of his increased responsibilities at bioMérieux. M. Bélingard joined NicOx's Board of Directors in 2002 and the Company would like to thank him for his invaluable support and advice during this period.

In September 2011, new preclinical results obtained with NCX 6560 were presented at the European Muscle Conference in Berlin (Germany), the annual meeting of the European Society for Muscle Research. NicOx also made several preclinical presentations at the 35th National Congress of the Italian Society of Pharmacology in Bologna (Italy) and at the Congress of the European Federation of IASP (International Association for the Study of Pain) Chapters in Hamburg (Germany).

The Company is continuing to work on implementing the previously disclosed business development strategy and to find innovative ways of securing alternative funding for early-stage projects to maximise the potential of its nitric oxide-donating platform.

Post-reporting period

NicOx and Ferrer Grupo have agreed to amend their collaboration for the development of NCX 1047, the lead preclinical candidate in their dermatology alliance, in order to enable NicOx to seek a development and marketing partner in the US. Ferrer will waive its option on US development and marketing rights to any product covered by the agreement, which was signed in April 2004[(1)] and expanded in September 2005[(2)]. Ferrer retains marketing rights for the European Union (including the European Free Trade Association, EFTA), Latin America, French-speaking Africa (including Morocco and Algeria) and Egypt. NicOx retains all rights for Asia and has the right to co-market products directly in the European Union and EFTA.

Review of the consolidated financial results for the nine months ended September 30, 2011 and 2010:

Revenues

NicOx did not record any revenues for the nine months ended September 30, 2011, compared to €7.4 million for the same period of 2010.

The revenues recognized during the first nine months of 2010 correspond to the initial license payment received from Bausch + Lomb following the signature of a licensing agreement in March 2010 that granted Bausch + Lomb exclusive worldwide rights to develop and commercialize BOL-303259-X (NCX 116). This amount has been immediately recognized in revenues because the Company will not have continuing involvement in the future development of the compound which is the subject of this collaboration agreement.

Research and development costs, general, administrative and selling costs

For the nine months ended September 30, 2011, research and development costs and general, administrative and selling costs were significantly reduced from the same period of 2010, amounting to €11.8 million compared to €41.4 million. This significant reduction results from the restructuring of the Group's entities and activities announced in 2010. As part of the restructuring, the US offices of NicOx were closed in August 2010, the headcount of the French and Italian entities of the Group were significantly reduced, and the activities were redefined in order to protect the Company's cash and cash equivalents and refocus the Group's key strategic priorities. For the first nine months of 2011, 61% of these expenses were attributable to research and development and 39% to selling and administrative expenses compared to 74% and 26%, respectively, for the same period of 2010.

Research and development expenses were €7.2 million in the nine months ended September 30, 2011, compared to €30.8 million during the nine months ended September 30, 2010. In the first nine months of 2011, research and development expenses correspond mainly to personnel expenses. The Group employed 39 people in research and development on September 30, 2011, compared to 73 people at the same date in 2010.

In the first nine months of 2011, general and administrative expenses were €3.4 million compared to €3.9 million on September 30, 2010, and include personnel expenses in administrative and financial functions, as well as the remuneration of corporate officers. Selling expenses totaled €1.3 million during the nine months ended September 30, 2011, compared to €6.7 million during the same period in 2010, and for 2011 relate to communication and business development activities (including the activities related to the evaluation of companies and products to acquire or in-licence). In 2010, these expenses also included preparation for the potential future commercialization of naproxcinod in the United States. On September 30, 2011, the Group employed 18 people in its selling, general and administrative departments, compared to 30 people at the same date in 2010.

Other income

Other income was €0.8 million at September 30, 2011 compared to €2.0 million at September 30, 2010. Other income relates to operational subsidies from research tax credits in France.

Other expenses

Other expenses exclusively relate to restructuring costs. These resulted in an income of €0.1 million on September 30, 2011 due to the cancellation of contingencies related to the restructuring of NicOx S.A recognized in 2010, which are no longer applicable in 2011.

For 2010, other expenses included an accrual of €4.7 million corresponding to estimated costs for the restructuring plan for NicOx SA's headquarters and Italian subsidiary; the cancellation of expenses in an amount of €1.4 million further to the cancellation of rights on stock options and free shares as a consequence of the restructuring plan and €2.5 million corresponding to the cost of the closure of the offices of NicOx Inc. in the US.

Operating result

The operating loss amounted to €10.9 million in the nine months ended September 30, 2011, compared to €37.7 million on September 30, 2010.

Other results

Net financial income totaled €0.7 million during the first nine months of 2011, compared to €0.2 million during the same period in 2010, and mainly represents the returns on the financial investments of the Company's cash and cash equivalents.

The income tax expense incurred by NicOx in the first nine months of 2011 relates to tax from its US and Italian subsidiaries and totaled €0.1 million, compared to €0.3 million during the same period in 2010.

Total net loss of the period

The total net loss was €10.4 million for the nine months ended September 30, 2011, compared to €37.8 million during the same period in 2010. This decrease is explained by the significant reduction of all the operating expenses following the restructuring implemented after the decision of the FDA not to approve naproxcinod in July 2010.

Consolidated statement of financial position

The indebtedness incurred by NicOx is mainly short-term operating debt. On September 30, 2011, the Company's current liabilities totaled €4.4 million, including €1.2 million in accrued compensation for employees, €1.2 million in taxes payable, €1.0 million in accounts payable to suppliers and external collaborators, €0.8 million in other contingencies and liabilities with respect to the restructuring cost accrued and €0.2 million for other liabilities.

The Company's cash and cash equivalents were €96.2 million on September 30, 2011, compared to €107.3 million on December 31, 2010 and €115.9 million on September 30, 2010.

(1) See NicOx press release dated April 29, 2004.

(2) See NicOx press release dated September 15, 2005.

About NicOx

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company focused on the research, development and future commercialization of drug candidates. NicOx is applying its proprietary nitric oxide-donating R&D platform to develop an internal portfolio of New Molecular Entities (NMEs) for the potential treatment of inflammatory, cardio-metabolic and ophthalmological diseases.

The Company's pipeline includes several nitric oxide-donating NMEs, which are in development internally and with partners, who include Merck (known as MSD outside the United States and Canada), Bausch + Lomb, and Ferrer.

NicOx S.A. is headquartered in France and is listed on Euronext Paris (Compartment B: Mid Caps).

COX
LISTED
NYSE
EURONEXT

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on NicOx's business are presented in the 4th chapter of the « *Document de référence, rapport financier annuel et rapport de gestion 2010* » filed with the French Autorité des Marchés Financiers (AMF) on February 25, 2011 and available on NicOx's website (www.nicox.com) and on the AMF's website (www.amf-france.org).

CONTACTS

NicOx — **Gavin Spencer • Vice President Business Development**
Tel +33 (0)4 97 24 53 00 • communications@nicox.com
www.nicox.com

Media Relations — **FTI Consulting**
Jonathan Birt • Tel : +44 (0)20 7269 7205 • jonathan.birt@fticonsulting.com

NicOx S.A.
Les Taissounières – Bât HB4 – 1681 route des Dolines – BP313 – 06906 Sophia Antipolis Cedex – France
Tel: +33 (0)4 97 24 53 00 • Fax: +33 (0)4 97 24 53 99

INTERIM CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME – SEPTEMBER 30, 2011

	For the period of nine months ended September 30,	
	2011	**2010**
	(in thousands of € except for per share data)	
Revenues…………………………………………………………	**-**	**7,423**
Research and development expenses………………………...…..	(7,160)	(30,754)
Administrative expenses………………………………………..	(3,395)	(3,940)
Selling expenses………………….……………………………..	(1,279)	(6,665)
Other income…………………...…………………………...	764	2,020
Other expense…………………………………………………..	141	(5,824)
Operating loss ………………………………………….....	**(10,929)**	**(37,740)**
Finance income ……….………….…………………………….	675	313
Finance expense………….…………….……………………….	(12)	(86)
Loss before income tax	**(10,266)**	**37,513**
Income tax expense…………………………………….......	(94)	(327)
Net loss of the period……………………….……………………	**(10,360)**	**(37,840)**
Exchange differences on translation of foreign operations………	-	15
Other comprehensive income (loss) for the period, net of tax	**-**	**-**
Total comprehensive income (loss) for the period, net of tax	**(10,360)**	**(37,825)**
Attributable to:		
- Equity holders of the parent	(10,360)	(37,825)
- Non-controlling interests	-	-
Basic and diluted loss per share attributable to equity holders of the parent…………………………………………………..	**(0.14)**	**(0.51)**

INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION – SEPTEMBER 30, 2011

	As of September 30, 2011	As of December 31, 2010
	(in thousands of €)	
ASSETS		
Non-current assets		
Property, plant & equipment	1,682	2,130
Intangible assets	258	386
Other financial assets	254	247
Deferred income tax assets	6	39
Total non-current assets	**2,200**	**2,802**
Current assets		
Government subsidies receivable	764	1,509
Other current assets	636	909
Prepaid expenses	334	377
Cash and cash equivalents	96,156	107,335
Total current assets	**97,890**	**110,130**
TOTAL ASSETS	**100,090**	**112,932**
EQUITY AND LIABILITIES		
Common shares	14,563	14,509
Other reserves	76,127	85,979
Non-controlling interests	-	-
Total Equity	**90,690**	**100,488**
Non-current liabilities		
Other contingencies and liabilities	4,871	4,548
Deferred income tax liabilities	105	96
Finance lease	65	83
Total non-current liabilities	**5,041**	**4,727**
Current liabilities		
Other contingencies and liabilities	761	2,800
Finance lease	30	30
Trade payables	1,005	2,045
Social security and other taxes	2,391	2,627
Other liabilities	172	215
Total current liabilities	**4,359**	**7,717**
TOTAL EQUITY AND LIABILITIES	**100,090**	**112,932**

NicOx S.A.
Les Taissounières – Bât HB4 – 1681 route des Dolines – BP313 – 06906 Sophia Antipolis Cedex – France
Tel: +33 (0)4 97 24 53 00 • Fax: +33 (0)4 97 24 53 99